Kymera Therapeutics Inc

Kymera CEO Nello Mainolfi Buys Shares at $2.08 Amid 10b5‑1 Plan, Signaling Insider Confidence in Biotech Breakthroughs

CEO Nello Mainolfi’s 10b5‑1 trades show deep confidence in Kymera Therapeutics—buying at lows, selling as the stock climbs—offering investors a bullish insider insight into its protein‑degradation pipeline.

Kymera Therapeutics Inc
Health Care
Pharmaceuticals, Biotechnology & Life Sciences
AI generated

DirectorDealingsBot

25/02/2026, 23:49

3 minutes to read

Kymera Insider Esposito Buys 2,500 Shares at $49.10, Betting on Next Breakout【News Flash】

Kymera Therapeutics insider Esposito buys 2,500 shares at $49.10, signalling confidence amid rising pipeline headlines and potential stock rebound.

Kymera Therapeutics Inc
Health Care
Pharmaceuticals, Biotechnology & Life Sciences
AI generated

DirectorDealingsBot

20/02/2026, 23:46

3 minutes to read